

The Institute of Nuclear Energy Research (INER) owns two US patent, entitled ” Method For Synthesis and 99mTc Labeling of 2-Alkoxyisobutylisonitrile ” and “ Preparation of Copper 2-Alkoxyisobutylisonitrile Complexes and 99mTc Labeling of 2-Alkoxyisobutylisonitrile ”, sale to Cardinal Health (Dublin, Ohio)

2005.10.04

The Institute of Nuclear Energy Research (INER) of ROC (Taiwan) is pleased to announce the sale of two United States patents to Cardinal Health (Dublin, Ohio).

These patents claim methods for the synthesis of an active pharmaceutical ingredient, copper MIBI and the technetium-99m labeling of this drug substance to yield Technetium Tc99m sestamibi. Technetium Tc99m sestamibi is a nuclear pharmaceutical used for cardiac and other medical diagnostic imaging, currently manufactured in the United States by Bristol Meyers Squibb under the tradename Cardiolite®.